PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs

• Published in: Journal of pharmaceutical sciences Vol. 105; no. 2; pp. 460 - 475
• Main Authors: Turecek, Peter L., Bossard, Mary J., Schoetens, Freddy, Ivens, Inge A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2016
• Subjects: Animals; biopharmaceuticals; Biopharmaceutics - methods; Chemistry, Pharmaceutical; Drug Approval; Drug-Related Side Effects and Adverse Reactions - metabolism; Humans; PEG reagent; PEGylation; PEGylation chemistry; Pharmaceutical Preparations - chemistry; Pharmaceutical Preparations - metabolism; polyethylene glycol; Polyethylene Glycols - adverse effects; Polyethylene Glycols - chemistry; Polyethylene Glycols - metabolism; Protein Stability; toxicology; toxicology; biopharmaceuticals; polyethylene glycol; PEGylation chemistry; PEGylation; PEG reagent
• ISSN: 0022-3549; 1520-6017
• DOI: 10.1016/j.xphs.2015.11.015

Modification of biopharmaceutical molecules by covalent conjugation of polyethylene glycol (PEG) molecules is known to enhance pharmacologic and pharmaceutical properties of proteins and other large molecules and has been used successfully in 12 approved drugs. Both linear and branched-chain PEG reagents with molecular sizes of up to 40 kDa have been used with a variety of different PEG derivatives with different linker chemistries. This review describes the properties of PEG itself, the history and evolution of PEGylation chemistry, and provides examples of PEGylated drugs with an established medical history. A trend toward the use of complex PEG architectures and larger PEG polymers, but with very pure and well-characterized PEG reagents is described. Nonclinical toxicology findings related to PEG in approved PEGylated biopharmaceuticals are summarized. The effect attributed to the PEG part of the molecules as observed in 5 of the 12 marketed products was cellular vacuolation seen microscopically mainly in phagocytic cells which is likely related to their biological function to absorb and remove particles and macromolecules from blood and tissues. Experience with marketed PEGylated products indicates that adverse effects in toxicology studies are usually related to the active part of the drug but not to the PEG moiety.